Jörg Spiegel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jörg Spiegel has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Klaus Fassbender
Department of Neurology Saarland University Homburg Germany
11 shared publications Ulrich Dillmann
Department of Neurology Saarland University Homburg/Saar Germany
6 shared publicationsSamer Ezziddin
Department of Nuclear Medicine Saarland University Homburg/Saar Germany
4 shared publications- Marcus Michael Unger
Department of Neurology, Saarland University, Homburg, Germany
3 shared publications - Ulrich Dillmann
Department of Neurology, Saarland University
3 shared publications Andrea Schaefer-Schuler
Department of Nuclear Medicine, Saarland University, D-66421, Homburg, Saar, Germany
2 shared publications
Latest Publications
- Open Access
- 25 November 2021
- Published by Oxford University Press (OUP) in Genomics, Proteomics & Bioinformatics
- Vol. 20 (2) , 274-287
Effects of Resistant Starch on Symptoms, Fecal Markers, and Gut Microbiota in Parkinson’s Disease — The RESISTA-PD Trial
The composition of the gut microbiota is linked to multiple diseases, including Parkinson’s disease (PD). Abundance of bacteria producing short-chain fatty acids (SCFAs) and fecal SCFA concentrations are reduced in PD. SCFAs exert various beneficial functions in humans. In the interventional, monocentric, open-label clinical trial “Effects of Resistant Starch on Bowel Habits, Short Chain Fatty Acids and Gut Microbiota in Parkinson ’s Disease” (RESISTA-PD; ID: NCT02784145), we aimed at altering fecal SCFAs by an 8-week prebiotic intervention with resistant starch (RS). We enrolled 87 subjects in three study-arms: 32 PD patients received RS (PD + RS), 30 control subjects received RS, and 25 PD patients received solely dietary instructions. We performed paired-end 100 bp length metagenomic sequencing of fecal samples using the BGISEQ platform at an average of 9.9 GB. RS was well-tolerated. In the PD + RS group, fecal butyrate concentrations increased significantly, and fecal calprotectin concentrations dropped significantly after 8 weeks of RS intervention. Clinically, we observed a reduction in non-motor symptom load in the PD + RS group. The reference-based analysis of metagenomes highlighted stable alpha-diversity and beta-diversity across the three groups, including bacteria producing SCFAs. Reference-free analysis suggested punctual, yet pronounced differences in the metagenomic signature in the PD + RS group. RESISTA-PD highlights that a prebiotic treatment with RS is safe and well-tolerated in PD. The stable alpha-diversity and beta-diversity alongside altered fecal butyrate and calprotectin concentrations call for long-term studies, also investigating whether RS is able to modify the clinical course of PD.
- 25 November 2021
- Published by Oxford University Press (OUP) in Genomics, Proteomics & Bioinformatics
- Vol. 20 (2) , 274-287
Open AccessEffects of Resistant Starch on Symptoms, Fecal Markers, and Gut Microbiota in Parkinson’s Disease — The RESISTA-PD Trial
The composition of the gut microbiota is linked to multiple diseases, including Parkinson’s disease (PD). Abundance of bacteria producing short-chain fatty acids (SCFAs) and fecal SCFA concentrations are reduced in PD. SCFAs exert various beneficial functions in humans. In the interventional, monocentric, open-label clinical trial “Effects of Resistant Starch on Bowel Habits, Short Chain Fatty Acids and Gut Microbiota in Parkinson ’s Disease” (RESISTA-PD; ID: NCT02784145), we aimed at altering fecal SCFAs by an 8-week prebiotic intervention with resistant starch (RS). We enrolled 87 subjects in three study-arms: 32 PD patients received RS (PD + RS), 30 control subjects received RS, and 25 PD patients received solely dietary instructions. We performed paired-end 100 bp length metagenomic sequencing of fecal samples using the BGISEQ platform at an average of 9.9 GB. RS was well-tolerated. In the PD + RS group, fecal butyrate concentrations increased significantly, and fecal calprotectin concentrations dropped significantly after 8 weeks of RS intervention. Clinically, we observed a reduction in non-motor symptom load in the PD + RS group. The reference-based analysis of metagenomes highlighted stable alpha-diversity and beta-diversity across the three groups, including bacteria producing SCFAs. Reference-free analysis suggested punctual, yet pronounced differences in the metagenomic signature in the PD + RS group. RESISTA-PD highlights that a prebiotic treatment with RS is safe and well-tolerated in PD. The stable alpha-diversity and beta-diversity alongside altered fecal butyrate and calprotectin concentrations call for long-term studies, also investigating whether RS is able to modify the clinical course of PD.
- Open Access
Effects of Resistant Starch on Symptoms, Fecal Markers and Gut Microbiota in Parkinson’s Disease – The RESISTA-PD Trial
The composition of the gut microbiome is linked to multiple diseases, including Parkinson’s disease (PD). Bacteria producing short-chain fatty acids (SCFAs) and fecal SCFA concentrations are reduced in PD. SCFAs exert various beneficial functions in humans. In the interventional, monocentric, open-label clinical trial RESISTA-PD ( NCT02784145 ) we aimed at altering fecal SCFAs by an 8-week prebiotic intervention with resistant starch (RS). We enrolled 87 subjects in three study-arms: 32 PD patients receiving RS (PD + RS), 30 control subjects receiving RS, and 25 PD patients receiving solely dietary instructions. We performed paired-end 100 base pair length metagenomic sequencing of fecal samples using the BGISEQ platform at an average of 9.9 GB. RS was well-tolerated. In PD + RS, fecal butyrate concentrations increased significantly and fecal calprotectin concentrations dropped significantly after 8 weeks of RS. Clinically, we observed a reduction in non-motor symptoms load in PD + RS. The reference-based analysis of metagenomes highlighted stable alpha-diversity and beta-diversity across the three groups, including bacteria producing SCFAs. Reference-free analysis suggested punctual, yet pronounced differences in the metagenomic signature in PD + RS. RESISTA-PD highlights that a prebiotic treatment with RS is safe and well-tolerated in PD. The stable alpha-diversity and beta-diversity alongside altered fecal butyrate and calprotectin concentrations calls for long-term studies, also investigating whether RS is able to modify the clinical course of PD.
Open AccessEffects of Resistant Starch on Symptoms, Fecal Markers and Gut Microbiota in Parkinson’s Disease – The RESISTA-PD Trial
The composition of the gut microbiome is linked to multiple diseases, including Parkinson’s disease (PD). Bacteria producing short-chain fatty acids (SCFAs) and fecal SCFA concentrations are reduced in PD. SCFAs exert various beneficial functions in humans. In the interventional, monocentric, open-label clinical trial RESISTA-PD ( NCT02784145 ) we aimed at altering fecal SCFAs by an 8-week prebiotic intervention with resistant starch (RS). We enrolled 87 subjects in three study-arms: 32 PD patients receiving RS (PD + RS), 30 control subjects receiving RS, and 25 PD patients receiving solely dietary instructions. We performed paired-end 100 base pair length metagenomic sequencing of fecal samples using the BGISEQ platform at an average of 9.9 GB. RS was well-tolerated. In PD + RS, fecal butyrate concentrations increased significantly and fecal calprotectin concentrations dropped significantly after 8 weeks of RS. Clinically, we observed a reduction in non-motor symptoms load in PD + RS. The reference-based analysis of metagenomes highlighted stable alpha-diversity and beta-diversity across the three groups, including bacteria producing SCFAs. Reference-free analysis suggested punctual, yet pronounced differences in the metagenomic signature in PD + RS. RESISTA-PD highlights that a prebiotic treatment with RS is safe and well-tolerated in PD. The stable alpha-diversity and beta-diversity alongside altered fecal butyrate and calprotectin concentrations calls for long-term studies, also investigating whether RS is able to modify the clinical course of PD.
- Open Access
- 20 July 2020
- Published by Wiley in Acta Neurologica Scandinavica
- Vol. 142 (4) , 385-391
Striatal dopamine transporters and cognitive function in Parkinson’s disease
Background Idiopathic Parkinson´s disease (PD) is characterized by clinical motor symptoms including hypokinesia, rigidity and tremor. In addition to the movement disorder, cognitive deficits are commonly described. In the present study, we applied FP‐CIT SPECT to investigate the impact of nigrostriatal dopaminergic degeneration on cognitive function in PD patients. Methods 54 PD patients underwent [123I]FP‐CIT SPECT and CERAD (Consortium to Establish a Registry for Alzheimer’s Disease) testing. FP‐CIT SPECT visualized the density of presynaptic dopamine transporters in both striata, each subdivided into a limbic, executive and sensorimotor subregion according to the atlas of Tziortzi et al. (2014). CERAD testing quantified cognitive function. Results In the CERAD testing, PD patients exhibited deficits in the domains of semantic memory, attention, visuospatial function, non‐verbal memory and executive function. After correction for multiple testing, the performance of the subtests Figure Recall and Trail Making Test A correlated significantly with FP‐CIT uptake into the ipsilateral executive subregion. The performance of the subtest Figure Saving correlated significantly with FP‐CIT uptake into the contralateral executive subregion. Conclusions The significant correlation between cognitive function and density of nigrostriatal dopamine transporters, as assessed by FP‐CIT SPECT, indicate that striatal dopaminergic pathways – primarily the executive striatal subregion – are relevant to cognitive processing in PD.
- 20 July 2020
- Published by Wiley in Acta Neurologica Scandinavica
- Vol. 142 (4) , 385-391
Open AccessStriatal dopamine transporters and cognitive function in Parkinson’s disease
Background Idiopathic Parkinson´s disease (PD) is characterized by clinical motor symptoms including hypokinesia, rigidity and tremor. In addition to the movement disorder, cognitive deficits are commonly described. In the present study, we applied FP‐CIT SPECT to investigate the impact of nigrostriatal dopaminergic degeneration on cognitive function in PD patients. Methods 54 PD patients underwent [123I]FP‐CIT SPECT and CERAD (Consortium to Establish a Registry for Alzheimer’s Disease) testing. FP‐CIT SPECT visualized the density of presynaptic dopamine transporters in both striata, each subdivided into a limbic, executive and sensorimotor subregion according to the atlas of Tziortzi et al. (2014). CERAD testing quantified cognitive function. Results In the CERAD testing, PD patients exhibited deficits in the domains of semantic memory, attention, visuospatial function, non‐verbal memory and executive function. After correction for multiple testing, the performance of the subtests Figure Recall and Trail Making Test A correlated significantly with FP‐CIT uptake into the ipsilateral executive subregion. The performance of the subtest Figure Saving correlated significantly with FP‐CIT uptake into the contralateral executive subregion. Conclusions The significant correlation between cognitive function and density of nigrostriatal dopamine transporters, as assessed by FP‐CIT SPECT, indicate that striatal dopaminergic pathways – primarily the executive striatal subregion – are relevant to cognitive processing in PD.
- 1 January 2020
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 70, 20-22
Impact of oral COMT-inhibitors on gut microbiota and short chain fatty acids in Parkinson's disease
- 1 January 2020
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 70, 20-22
Impact of oral COMT-inhibitors on gut microbiota and short chain fatty acids in Parkinson's disease
- 1 September 2019
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 66, 247-248
MIBG scintigraphy of the major salivary glands in progressive supranuclear palsy and corticobasal degeneration
- 1 September 2019
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 66, 247-248
MIBG scintigraphy of the major salivary glands in progressive supranuclear palsy and corticobasal degeneration
- 1 August 2018
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 53, 112-114
MIBG scintigraphy of the major salivary glands in multiple system atrophy
- 1 August 2018
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 53, 112-114
MIBG scintigraphy of the major salivary glands in multiple system atrophy
- 15 October 2016
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 34, 26-30
Reduced MIBG accumulation of the parotid and submandibular glands in idiopathic Parkinson's disease
- 15 October 2016
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 34, 26-30
Reduced MIBG accumulation of the parotid and submandibular glands in idiopathic Parkinson's disease
- Open Access
- 25 April 2014
- Published by Hindawi Limited in Acta Neurologica Scandinavica
- Vol. 130 (3) , 164-171
Nicotinicα4β2acetylcholine receptors and cognitive function in Parkinson's disease
Background Idiopathic Parkinson's disease (IPD) is characterized by the clinical motor symptoms of hypokinesia, rigidity, and tremor. Apart from these motor symptoms, cognitive deficits often occur in IPD. The positive effect of cholinesterase inhibitors on cognitive deficits in IPD and findings of earlier molecular imaging studies suggest that the cholinergic system plays an important role in the origin of cognitive decline in IPD. Methods Twenty‐five non‐demented patients with IPD underwent a 5‐[123I]iodo‐3‐[2(S)‐2‐azetidinylmethoxy]pyridine (5‐I‐A‐85380) SPECT to visualize α4β2 nicotinic acetylcholine receptors (nAchR) and cognitive testing with the CERAD (Consortium to Establish a Registry for Alzheimer's Disease) battery to identify domains of cognitive dysfunction. Results In the CERAD, the IPD patients exhibited deficits in non‐verbal memory, attention, psychomotor velocity, visuoconstructive ability, and executive functions. After Bonferroni correction for multiple comparisons, we found significant correlations between performance of the CERAD subtests Boston Naming Test (a specific test for visual perception and for detection of word‐finding difficulties) and Word List Intrusions (a specific test for learning capacity and memory for language information) vs binding of α4β2 nAchR in cortical (the right superior parietal lobule) and subcortical areas (the left thalamus, the left posterior subcortical region, and the right posterior subcortical region). Conclusions These significant correlations between the results of the CERAD subtests and the cerebral α4β2 nAchR density, as assessed by 5‐I‐A‐85380 SPECT, indicate that cerebral cholinergic pathways are relevant to cognitive processing in IPD.
- 25 April 2014
- Published by Hindawi Limited in Acta Neurologica Scandinavica
- Vol. 130 (3) , 164-171
Open AccessNicotinicα4β2acetylcholine receptors and cognitive function in Parkinson's disease
Background Idiopathic Parkinson's disease (IPD) is characterized by the clinical motor symptoms of hypokinesia, rigidity, and tremor. Apart from these motor symptoms, cognitive deficits often occur in IPD. The positive effect of cholinesterase inhibitors on cognitive deficits in IPD and findings of earlier molecular imaging studies suggest that the cholinergic system plays an important role in the origin of cognitive decline in IPD. Methods Twenty‐five non‐demented patients with IPD underwent a 5‐[123I]iodo‐3‐[2(S)‐2‐azetidinylmethoxy]pyridine (5‐I‐A‐85380) SPECT to visualize α4β2 nicotinic acetylcholine receptors (nAchR) and cognitive testing with the CERAD (Consortium to Establish a Registry for Alzheimer's Disease) battery to identify domains of cognitive dysfunction. Results In the CERAD, the IPD patients exhibited deficits in non‐verbal memory, attention, psychomotor velocity, visuoconstructive ability, and executive functions. After Bonferroni correction for multiple comparisons, we found significant correlations between performance of the CERAD subtests Boston Naming Test (a specific test for visual perception and for detection of word‐finding difficulties) and Word List Intrusions (a specific test for learning capacity and memory for language information) vs binding of α4β2 nAchR in cortical (the right superior parietal lobule) and subcortical areas (the left thalamus, the left posterior subcortical region, and the right posterior subcortical region). Conclusions These significant correlations between the results of the CERAD subtests and the cerebral α4β2 nAchR density, as assessed by 5‐I‐A‐85380 SPECT, indicate that cerebral cholinergic pathways are relevant to cognitive processing in IPD.
- 18 October 2013
- Published by Springer Nature in Journal of Neurology
- Vol. 261 (1) , 45-51
Is reduced myocardial sympathetic innervation associated with clinical symptoms of autonomic impairment in idiopathic Parkinson’s disease?
Patients with idiopathic Parkinson’s disease (IPD) have a reduced myocardial MIBG uptake in MIBG scintigraphy, indicating myocardial sympathetic denervation. We were interested whether this myocardial sympathetic denervation coincides with clinical symptoms of autonomic impairment in IPD patients. We performed MIBG scintigraphy, the SCOPA-AUT scale, a standardized medical history (developed in our clinic) and autonomic nervous system testing in 47 IPD patients (21 female, 26 male patients). We correlated myocardial MIBG uptake with the results of the SCOPA-AUT scale, the standardized medical history and the autonomic nervous system testing through the use of Spearman’s correlation. Myocardial MIBG uptake correlated significantly (p < 0.05) with several items of the SCOPA-AUT scale (in female patients: perspiration during the night, in male patients: sum score, saliva dribbling of the mouth, difficulty swallowing, fainting, constipation), of the standardized medical history (in male patients: swollen ankles) and of the autonomic nervous system testing (all patients: sum score, Ewing orthostasis test). Remarkably, we found more significant correlations in male than in female patients. Reduced myocardial sympathetic innervation—as revealed by MIBG scintigraphy—is associated with clinical symptoms of autonomic impairment. This association is more pronounced in male than in female patients. The cause for this gender-specific phenomenon is unclear.
- 18 October 2013
- Published by Springer Nature in Journal of Neurology
- Vol. 261 (1) , 45-51
Is reduced myocardial sympathetic innervation associated with clinical symptoms of autonomic impairment in idiopathic Parkinson’s disease?
Patients with idiopathic Parkinson’s disease (IPD) have a reduced myocardial MIBG uptake in MIBG scintigraphy, indicating myocardial sympathetic denervation. We were interested whether this myocardial sympathetic denervation coincides with clinical symptoms of autonomic impairment in IPD patients. We performed MIBG scintigraphy, the SCOPA-AUT scale, a standardized medical history (developed in our clinic) and autonomic nervous system testing in 47 IPD patients (21 female, 26 male patients). We correlated myocardial MIBG uptake with the results of the SCOPA-AUT scale, the standardized medical history and the autonomic nervous system testing through the use of Spearman’s correlation. Myocardial MIBG uptake correlated significantly (p < 0.05) with several items of the SCOPA-AUT scale (in female patients: perspiration during the night, in male patients: sum score, saliva dribbling of the mouth, difficulty swallowing, fainting, constipation), of the standardized medical history (in male patients: swollen ankles) and of the autonomic nervous system testing (all patients: sum score, Ewing orthostasis test). Remarkably, we found more significant correlations in male than in female patients. Reduced myocardial sympathetic innervation—as revealed by MIBG scintigraphy—is associated with clinical symptoms of autonomic impairment. This association is more pronounced in male than in female patients. The cause for this gender-specific phenomenon is unclear.
- 15 March 2013
- Published by Georg Thieme Verlag KG in Fortschritte der Neurologie · Psychiatrie
- Vol. 81 (04) , 206-209
Erstmanifestation eines organischen manisch-schizophreniformen Syndroms mit nachfolgender Katatonie bei NMDA-Rezeptor-Antikörper-positiver Encephalitis
Wir berichten über eine 39-jährige Patientin mit ausgeprägter Katatonie nach zuvor über sechs Monate progredientem schizomanischen Syndrom. Klinisch zeigten sich bei Aufnahme eine Katatonie, ein tetraspastisches Syndrom und fokale epileptische Anfälle. Kernspintomografisch kamen kontrastmittelaffine Signalsteigerungen im beidseitigen subkortikalen Marklager zur Darstellung. Im Liquor zeigte sich eine lymphozytäre Pleozytose mit autochthonen oligoklonalen Banden. Im Serum waren reproduzierbar Antikörper gegen den NMDA-NR-1-Rezeptor nachweisbar. Eine ausführliche Tumorsuche erbrachte ein negatives Ergebnis, auch hinsichtlich des Vorliegens einer Ovarialneoplasie, welche bei der paraneoplastischen Form der NMDA-Rezeptor-Antikörper-positiven Enzephalitis häufig anzutreffen ist. Wir gehen daher von einer autoimmunen, nicht paraneoplastischen Enzephalitis aus. Unter immunsuppressiver Therapie initial mit Glukokortikoiden und im Verlauf mit Rituximab kam es zu einer schrittweisen deutlichen Besserung der Symptomatik. Dieser Fall zeigt, dass bei erstmaliger psychotischer Symptomatik nach einer NMDA-Rezeptor-Antikörper-positiven Enzephalitis gefahndet werden sollte. We report on a 39-year-old female patient who developed catatonia after there had been schizomanic symptoms in the six months before. At admission the patient exhibited catatonia, a tetraspastic syndrome and focal epileptic seizures. The cranial MRI revealed bilateral subcortical hyperintense lesions which took up contrast agent. Examination of the cerebrospinal fluid disclosed a lymphocytic pleocytosis and autochthone oligoclonal bands. In the serum autoantibodies against the NMDA-NR-1 receptor were reproducibly detected. A detailed search for a tumour was negative. In detail, we could exclude a neoplasm of the ovaries which is often present in the paraneoplastic type of anti-NMDA-receptor encephalitis. Therefore we assume an autoimmune, not paraneoplastic, encephalitis in our patient. The symptoms improved significantly after an immunosuppressive therapy – initially with glucocorticoids followed by rituximab – had been initiated. This case illustrates that an autoimmune encephalitis should be looked for when first psychotic symptoms occur.
- 15 March 2013
- Published by Georg Thieme Verlag KG in Fortschritte der Neurologie · Psychiatrie
- Vol. 81 (04) , 206-209
Erstmanifestation eines organischen manisch-schizophreniformen Syndroms mit nachfolgender Katatonie bei NMDA-Rezeptor-Antikörper-positiver Encephalitis
Wir berichten über eine 39-jährige Patientin mit ausgeprägter Katatonie nach zuvor über sechs Monate progredientem schizomanischen Syndrom. Klinisch zeigten sich bei Aufnahme eine Katatonie, ein tetraspastisches Syndrom und fokale epileptische Anfälle. Kernspintomografisch kamen kontrastmittelaffine Signalsteigerungen im beidseitigen subkortikalen Marklager zur Darstellung. Im Liquor zeigte sich eine lymphozytäre Pleozytose mit autochthonen oligoklonalen Banden. Im Serum waren reproduzierbar Antikörper gegen den NMDA-NR-1-Rezeptor nachweisbar. Eine ausführliche Tumorsuche erbrachte ein negatives Ergebnis, auch hinsichtlich des Vorliegens einer Ovarialneoplasie, welche bei der paraneoplastischen Form der NMDA-Rezeptor-Antikörper-positiven Enzephalitis häufig anzutreffen ist. Wir gehen daher von einer autoimmunen, nicht paraneoplastischen Enzephalitis aus. Unter immunsuppressiver Therapie initial mit Glukokortikoiden und im Verlauf mit Rituximab kam es zu einer schrittweisen deutlichen Besserung der Symptomatik. Dieser Fall zeigt, dass bei erstmaliger psychotischer Symptomatik nach einer NMDA-Rezeptor-Antikörper-positiven Enzephalitis gefahndet werden sollte. We report on a 39-year-old female patient who developed catatonia after there had been schizomanic symptoms in the six months before. At admission the patient exhibited catatonia, a tetraspastic syndrome and focal epileptic seizures. The cranial MRI revealed bilateral subcortical hyperintense lesions which took up contrast agent. Examination of the cerebrospinal fluid disclosed a lymphocytic pleocytosis and autochthone oligoclonal bands. In the serum autoantibodies against the NMDA-NR-1 receptor were reproducibly detected. A detailed search for a tumour was negative. In detail, we could exclude a neoplasm of the ovaries which is often present in the paraneoplastic type of anti-NMDA-receptor encephalitis. Therefore we assume an autoimmune, not paraneoplastic, encephalitis in our patient. The symptoms improved significantly after an immunosuppressive therapy – initially with glucocorticoids followed by rituximab – had been initiated. This case illustrates that an autoimmune encephalitis should be looked for when first psychotic symptoms occur.